Moreover, tumor cells with loss of H3K36me3 due to mutation in SETD2, the gene that encodes a histone lysine methyltransferase, or mutation in histone H3 itself showed HR, NHEJ, and MMR impairment and sensitivity to WEE1, CHK, or ATR inhibitors [181]. Here, SETD2 is linked to neoplasm.